Field C S, Ory S J, Wahner H W, Herrmann R R, Judd H L, Riggs B L
Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905.
Am J Obstet Gynecol. 1993 Jan;168(1 Pt 1):114-21. doi: 10.1016/s0002-9378(12)90897-2.
The purpose of our study was to evaluate the effects of three dosages of transdermally administered 17 beta-estradiol on markers of bone loss in women who had recently undergone surgical menopause.
This was a 2-year, randomized, double-blind, placebo-controlled study that reviewed 127 women stratified by age. Biochemical indicators of bone metabolism in urine and serum were periodically assessed, as was bone mineral content of the lumbar spine and radius. Statistical analysis examined the percent changes from baseline in bone mineral density by using an analysis of covariance with treatment as a factor and the baseline value as a covariant, by performing all-pairwise comparisons among the three estradiol groups, and by testing for a linear dose-response relationship.
After 2 years of therapy, a significant dose-response relationship was detected.
This 2-year study demonstrates that transdermally administered 17 beta-estradiol is a safe and effective regimen for preventing bone loss in recently postmenopausal women.
我们研究的目的是评估三种剂量经皮给药的17β-雌二醇对近期经历手术绝经的女性骨质流失标志物的影响。
这是一项为期2年的随机、双盲、安慰剂对照研究，对127名按年龄分层的女性进行了评估。定期评估尿液和血清中骨代谢的生化指标，以及腰椎和桡骨的骨矿物质含量。统计分析通过将治疗作为一个因素、基线值作为协变量进行协方差分析，通过在三个雌二醇组之间进行所有成对比较，以及通过测试线性剂量反应关系，来检查骨矿物质密度相对于基线的变化百分比。
经过2年的治疗，检测到显著的剂量反应关系。
这项为期2年的研究表明，经皮给药的17β-雌二醇是预防近期绝经后女性骨质流失的一种安全有效的治疗方案。
